Marya D Zilberberg1, Andrew F Shorr. 1. EviMed Research Group, LLC, Goshen, Massachusetts; Department of Public Health, University of Massachusetts, Amherst, Massachusetts.
Abstract
BACKGROUND: Antimicrobial resistance complicates antibiotic selection. Pseudomonas aeruginosa (PA), common in pneumonia and blood stream infections (BSIs), is frequently resistant to multiple antimicrobial classes. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a pathogen of concern over the past decade. OBJECTIVE: To determine the prevalence of CRE and multidrug-resistant PA (MDR-PA) in pneumonia and BSI hospitalizations. DESIGN: Survey of data from a nationally representative sample of microbiology laboratories in 217 hospitals in the United States. METHODS/ SETTING: We examined Eurofins' The Surveillance Network database from 2000 to 2009 to explore the proportion of all PA in pneumonia and BSI that is MDR. We performed the same analysis for CRE as a proportion of Enterobacteriaceae. We defined MDR-PA as any isolate resistant to ≥3 drug classes. Enterobacteriaceae were CRE if resistant to both a third generation cephalosporin and a carbapenem. RESULTS: We identified 205,526 PA (187,343 pneumonia; 18,183 BSI) and 95,566 Enterobacteriaceae specimens (58,810 pneumonia; 36,756 BSI). The prevalence of MDR-PA was ∼15-fold higher than CRE in both infection types (pneumonia: 22.0% MDR-PA vs 1.6% CRE; BSI: 14.7% MDR-PA vs 1.1% CRE). There was a net rise in MDR-PA as a proportion of all PA from 2000 to 2009 (BSI: 10.7%-13.5%; pneumonia: 19.2%-21.7%). The CRE phenotype emerged in 2002 in both infection types, peaking in 2008 at 3.6% in BSI and 5.3% in pneumonia, and stabilized thereafter. CONCLUSIONS: Although CRE organisms have emerged as an important pathogen in BSI and pneumonia, MDR-PA remains more prevalent in the United States.
BACKGROUND: Antimicrobial resistance complicates antibiotic selection. Pseudomonas aeruginosa (PA), common in pneumonia and blood stream infections (BSIs), is frequently resistant to multiple antimicrobial classes. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a pathogen of concern over the past decade. OBJECTIVE: To determine the prevalence of CRE and multidrug-resistant PA (MDR-PA) in pneumonia and BSI hospitalizations. DESIGN: Survey of data from a nationally representative sample of microbiology laboratories in 217 hospitals in the United States. METHODS/ SETTING: We examined Eurofins' The Surveillance Network database from 2000 to 2009 to explore the proportion of all PA in pneumonia and BSI that is MDR. We performed the same analysis for CRE as a proportion of Enterobacteriaceae. We defined MDR-PA as any isolate resistant to ≥3 drug classes. Enterobacteriaceae were CRE if resistant to both a third generation cephalosporin and a carbapenem. RESULTS: We identified 205,526 PA (187,343 pneumonia; 18,183 BSI) and 95,566 Enterobacteriaceae specimens (58,810 pneumonia; 36,756 BSI). The prevalence of MDR-PA was ∼15-fold higher than CRE in both infection types (pneumonia: 22.0% MDR-PA vs 1.6% CRE; BSI: 14.7% MDR-PA vs 1.1% CRE). There was a net rise in MDR-PA as a proportion of all PA from 2000 to 2009 (BSI: 10.7%-13.5%; pneumonia: 19.2%-21.7%). The CRE phenotype emerged in 2002 in both infection types, peaking in 2008 at 3.6% in BSI and 5.3% in pneumonia, and stabilized thereafter. CONCLUSIONS: Although CRE organisms have emerged as an important pathogen in BSI and pneumonia, MDR-PA remains more prevalent in the United States.
Authors: Chhinder P Sodhi; Jenny Nguyen; Yukihiro Yamaguchi; Adam D Werts; Peng Lu; Mitchell R Ladd; William B Fulton; Mark L Kovler; Sanxia Wang; Thomas Prindle; Yong Zhang; Eric D Lazartigues; Michael J Holtzman; John F Alcorn; David J Hackam; Hongpeng Jia Journal: J Immunol Date: 2019-10-23 Impact factor: 5.422
Authors: Dee Shortridge; Mariana Castanheira; Michael A Pfaller; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: A Walkty; H Adam; M Baxter; A Denisuik; P Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: Anne E Marsden; Jessica M King; M Ashley Spies; Oak K Kim; Timothy L Yahr Journal: Antimicrob Agents Chemother Date: 2015-11-16 Impact factor: 5.191
Authors: Deanna J Buehrle; Ryan K Shields; Liang Chen; Binghua Hao; Ellen G Press; Ammar Alkrouk; Brian A Potoski; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191